PCSK9: a target for hypercholesterolaemia in nephrotic syndrome

被引：6
|
作者：
Alan W. J. Morris
机构：
来源：
Nature Reviews Nephrology | 2016年 / 12卷 / 9期
关键词：
D O I：
10.1038/nrneph.2016.111
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：510 / 510
相关论文
共 50 条
  • [21] Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation
    Kuehl, Michael
    Binner, Christian
    Jozwiak, Joanna
    Fischer, Julia
    Hahn, Jochen
    Addas, Alaeldin
    Dinov, Boris
    Garbade, Jens
    Hindricks, Gerhard
    Borger, Michael
    PLOS ONE, 2019, 14 (01):
  • [22] New Pharmacological Approaches to Target PCSK9
    Catapano, Alberico L.
    Pirillo, Angela
    Norata, Giuseppe D.
    CURRENT ATHEROSCLEROSIS REPORTS, 2020, 22 (07)
  • [23] PCSK9 as a therapeutic target for cardiovascular disease
    Zhang, Pei-Ying
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2017, 13 (03) : 810 - 814
  • [24] Three different therapies to target PCSK9
    Andrew Robson
    Nature Reviews Cardiology, 2021, 18 : 541 - 541
  • [25] PCSK9:: a promising therapeutic target for dyslipidemias?
    Lambert, G
    Krempf, M
    Costet, P
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2006, 17 (03): : 79 - 81
  • [26] PCSK9: A Potential Therapeutic Target for Sepsis
    Yuan, Yuan
    Wu, Wei
    Sun, Shanshan
    Zhang, Yi
    Chen, Zhi
    JOURNAL OF IMMUNOLOGY RESEARCH, 2020, 2020
  • [27] The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation
    Noguchi, Tohru
    Katsuda, Shoji
    Kawashiri, Masa-aki
    Tada, Hayato
    Nohara, Atsushi
    Inazu, Akihiro
    Yamagishi, Masakazu
    Kobayashi, Junji
    Mabuchi, Hiroshi
    ATHEROSCLEROSIS, 2010, 210 (01) : 166 - 172
  • [28] New Pharmacological Approaches to Target PCSK9
    Alberico L. Catapano
    Angela Pirillo
    Giuseppe D. Norata
    Current Atherosclerosis Reports, 2020, 22
  • [29] PCSK9 as new target in hyperlipidemia treatment
    Stawowy, P.
    Kelle, S.
    Fleck, E.
    HERZ, 2014, 39 (04) : 466 - 469
  • [30] Three different therapies to target PCSK9
    Robson, Andrew
    NATURE REVIEWS CARDIOLOGY, 2021, 18 (08) : 541 - 541
12345